OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
March 22, 2023
The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.
March 13, 2023
Higher baseline Disease Activity Index for Psoriatic Arthritis (DAPSA) was associated with reduced probability of achieving low disease activity or remission.
February 23, 2023
Study results are the first to demonstrate that tofacitinib may be an effective treatment option for Chinese patients with active psoriatic arthritis.
February 15, 2023
In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of a study that evaluated the retention rate and safety of ixekizumab in patients with psoriatic arthritis in real clinical practice conditions.